Clinical observation of carbocisteine combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of stable COPD of group D
Author(s): JING Jun-hu, LI Li-yu, Tianjin Fourth Center Hospital
Pages: 1392-1395
Year: 2014 Issue: 12
Journal: World Phytomedicines
Keyword: Carbocisteine Oral Solution; Salmeterol Xinafoate and Fluticasone Propionate Aerosol; chronic obstructive pulmonary disease; mMRC;
Abstract: Objective To investigate the clinical effect of carbocisteine combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of stable chronic obstructive pulmonary disease(COPD) of group D. Methods The patients with stable COPD of group D(96 cases) of Tianjin Fourth Center Hospital from August 2011 to June 2013 were randomly divided into treatment(n = 50) and control(n = 46) groups. The patients in the treatment group were administered with Salmeterol Xinafoate and Fluticasone Propionate Aerosol on the basis of conventional treatment, 1 press/time, twice daily. The patients in the treatment group were po administered with Carbocisteine Oral Solution at the basis of the control group, 10 m L/time, three times daily. The patients in two groups were treated for 48 weeks. The changes of exercise tolerance, dyspnea index(m MRC), and pulmonary function in two groups before treatment, and treated for 8, 24, and 48 weeks were observed. At the same time, the number of exacerbation were observed in the process of treatment. Results 6MWDS in two groups was significant increased, the m MRC was reduced in 8, 24, and 48 weeks of treatment, and the difference was statistically significant in the same group before and after treatment(P < 0.05). 6MWDS of the treatment group was longer and m MRC was significantly lower than that in the control group in 24 and 48 weeks of treatment, and there were differences between the two groups(P < 0.05). FEV1 and FEV1/pred% in two groups were increased in 24 and 48 weeks of treatment, and the difference was statistically significant in the same group before and after treatment(P < 0.05). FEV1 and FEV1/pred% in treatment group were higher than those in the control group in 24 and 48 weeks of treatment, and there were differences between the two groups(P < 0.05). Conclusion Carbocisteine combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol has the good clinical effect in treatment of stable COPD of group D, and can increase exercise endurance, while can improve the symptoms of dyspnea and lung function, which is worth clinical promotion.
Pages: 1392-1395
Year: 2014 Issue: 12
Journal: World Phytomedicines
Keyword: Carbocisteine Oral Solution; Salmeterol Xinafoate and Fluticasone Propionate Aerosol; chronic obstructive pulmonary disease; mMRC;
Abstract: Objective To investigate the clinical effect of carbocisteine combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of stable chronic obstructive pulmonary disease(COPD) of group D. Methods The patients with stable COPD of group D(96 cases) of Tianjin Fourth Center Hospital from August 2011 to June 2013 were randomly divided into treatment(n = 50) and control(n = 46) groups. The patients in the treatment group were administered with Salmeterol Xinafoate and Fluticasone Propionate Aerosol on the basis of conventional treatment, 1 press/time, twice daily. The patients in the treatment group were po administered with Carbocisteine Oral Solution at the basis of the control group, 10 m L/time, three times daily. The patients in two groups were treated for 48 weeks. The changes of exercise tolerance, dyspnea index(m MRC), and pulmonary function in two groups before treatment, and treated for 8, 24, and 48 weeks were observed. At the same time, the number of exacerbation were observed in the process of treatment. Results 6MWDS in two groups was significant increased, the m MRC was reduced in 8, 24, and 48 weeks of treatment, and the difference was statistically significant in the same group before and after treatment(P < 0.05). 6MWDS of the treatment group was longer and m MRC was significantly lower than that in the control group in 24 and 48 weeks of treatment, and there were differences between the two groups(P < 0.05). FEV1 and FEV1/pred% in two groups were increased in 24 and 48 weeks of treatment, and the difference was statistically significant in the same group before and after treatment(P < 0.05). FEV1 and FEV1/pred% in treatment group were higher than those in the control group in 24 and 48 weeks of treatment, and there were differences between the two groups(P < 0.05). Conclusion Carbocisteine combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol has the good clinical effect in treatment of stable COPD of group D, and can increase exercise endurance, while can improve the symptoms of dyspnea and lung function, which is worth clinical promotion.
Related Articles